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Novel Anti-Inflammatory Properties of the
Angiogenesis Inhibitor Vasostatin
Rainer Huegel1,3, Paula Velasco1,3, Maria De La Luz Sierra2, Enno Christophers1, Jens M. Schro¨der1,
Thomas Schwarz1, Giovanna Tosato2 and Bernhard Lange-Asschenfeldt1
Endothelial cells are critically involved in the pathogenesis of inflammation, which is characterized by
vasopermeability, plasma leakage, leukocyte recruitment, and neovascularization. Therefore, inhibitors of
endothelial cell function could reduce inflammation. In this study, we evaluated the effects of the angiogenesis
inhibitor vasostatin on inflammations induced by contact hypersensitivity reactions in mouse ears. Vasostatin-
treated mice revealed significantly reduced edema formation, resulting from lower plasma leakage and
inhibition of inflammation-associated vascular remodeling. Intravital microscopy studies of inflamed ears
showed a decrease in the fraction of rolling leukocytes in vasostatin-treated mice, and Lycopersicon esculentum
lectin-perfused ears revealed fewer leukocytes adherent to the vessel wall. The inflammatory infiltrate from
vasostatin-treated mice was characterized by fewer CD8þ T cells, neutrophils, and macrophages compared to
the saline-treated animals. In a modified Miles assay, vasostatin inhibited vascular endothelial growth factor-A-
induced permeability, and inflamed ear tissues from vasostatin-treated mice expressed significantly reduced
levels of the vascular destabilizer angiopoietin-2. These results reveal a previously unrecognized anti-
inflammatory property of the angiogenesis inhibitor vasostatin, and suggest that vasostatin is a potential
candidate drug for the treatment of inflammation.
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INTRODUCTION
The vascular endothelium is an important component of the
inflammatory response and manifests striking changes during
inflammation. As a result, vascular hyperpermeability, tissue
edema, and perivascular inflammatory infiltrate characterize
inflamed tissues. Moreover, endothelial cells are an impor-
tant source of proinflammatory and proangiogenic factors.
Therefore, the increased vascular surface area resulting from
inflammation-associated angiogenesis is an important com-
ponent of inflammations, as it translates to an extended
capacity for cytokine production, adhesion molecule expres-
sion, and leukocyte recruitment (Jackson et al., 1997). In fact,
there is accumulating experimental evidence that angiogen-
esis and inflammation are closely interlinked (Braverman and
Sibley, 1982; Jackson et al., 1997; Lange-Asschenfeldt et al.,
2002; Oura et al., 2002; Kunstfeld et al., 2004).
The experimental contact hypersensitivity (CHS) reaction
is a model for an acute inflammatory response that is
accompanied by a robust increase in the index of proliferat-
ing endothelial cells (Polverini et al., 1977). This model has
been utilized to demonstrate that angiogenesis factors
modulate inflammation. For instance, mice that overexpress
the proangiogenic factors, vascular endothelial growth factor-
A (VEGF-A) (Kunstfeld et al., 2004) or placental growth factor
(Oura et al., 2002), react with an exaggerated ear swelling
response associated with increased edema formation and
vascular remodeling. In contrast, the CHS response in
placental growth factor-deficient mice is much less pro-
nounced (Oura et al., 2002). Meanwhile, mice that lack the
angioinhibitor thrombospondin-2 exhibited a prolonged and
persistent inflammation accompanied by enlarged vessels
(Lange-Asschenfeldt et al., 2002). The positive correlation
between enhanced vascularity and increased inflammatory
responses and the abundance of factors that modulate
angiogenesis known to be upmodulated during inflammatory
responses (Detmar et al., 1994; Brown et al., 1995; Dvorak
et al., 1995; Schroder and Mochizuki, 1999; Kuroda et al.,
2001; Oura et al., 2002; Scott et al., 2002) confirm that the
endothelium is active and relevant in the pathophysiology of
inflammatory diseases.
However, studies addressing the physiological role of
angiogenesis inhibitors during inflammation and potential
therapeutic approaches with these factors in inflammation
remain scant. In the past years, it has been demonstrated that
blocking VEGF-A signaling resulted in suppressed edema
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formation in experimental inflammations. Furthermore, fol-
lowing treatment with the angiogenesis inhibitors TNP-470,
caplostatin, and angiostatin, vascular leakage was reduced in
experimental inflammations. In this study, we assessed the
effect of a treatment regimen with the naturally occurring
angiogenesis inhibitor vasostatin (Pike et al., 1998, 1999) in
an experimental CHS reaction in mice sensitized against
oxazolone.
Vasostatin, an endothelial cell inhibitory factor originally
isolated in culture supernatants of Epstein–Barr virus-immor-
talized cells, consists of the amino-terminal domain of
calreticulin inclusive of residues 1–180. Vasostatin inhibits
the proliferation of endothelial cells stimulated with basic
fibroblast growth factor and VEGF-A and suppresses neo-
vascularization and tumor growth in vivo. (Pike et al., 1998,
1999). Here, we report that systemic treatment with
recombinant vasostatin resulted in a diminished inflamma-
tory response in the ear skin of mice. We observed reduced
edema formation, leukocyte recruitment, and vascular
remodeling following vasostatin treatment. Moreover,
vasostatin potently inhibited VEGF-A-induced permeability
in vivo and inhibited the upregulation of the vascular
destabilizer angiopoietin (Ang)-2 observed in the inflamed
lesions. Our study reveals a novel function for the angiogen-
esis inhibitor vasostatin as an anti-inflammatory substance,
suggesting that therapeutic strategies using vasostatin and
other angiogenesis antagonists could represent a novel
approach for the treatment of inflammations.
RESULTS
Vasostatin reduced experimentally induced cutaneous
inflammation and vascular leakage
Mice sensitized to oxazolone by topical application on the
abdomen and paws were challenged with topical application
of oxazolone to the right ear. The left ear was treated with
vehicle alone. Before oxalozone challenge, mice were
treated intraperitoneally with vasostatin (130 mg/mouse; 24
and 2 hours before challenge) and treatment continued every
24 hours in the post-challenge period. Twenty-four and
48 hours after the onset of a CHS, we observed 38 and 31%
(Po0.001) less edema, respectively, in the vasostatin-treated
compared to the saline-treated mice in the mouse ear swelling
test (Figure 1a). This effect of vasostatin was observed
throughout the recovery period of 7 days: 72 hours post-
challenge and thereafter, we observed 50% less edema in the
vasostatin-treated ears compared to the saline-treated skin.
To quantify the observed diminished edema formation in
the inflamed skin of vasostatin-treated mice, we performed
Evans blue leakage assays. Twenty-four hours after the
induction of the CHS, we observed 43% less plasma
extravasation of Evans blue dye (EBD) into the inflamed
skin of vasostatin-treated compared to the saline-treated
mice (243.4728.4 ng EBD/mg tissue, saline-treated;
138.4724.0 ng EBD/mg tissue, vasostatin-treated; Po0.05)
(Figure 1b). Histological analysis of the inflamed murine ear
skins 24 and 48 hours after the onset of CHS confirmed
decreased edema formation following vasostatin treatment
(Figure 1c). The morphology of blood vessels in the inflamed
skin of vasostatin- and saline-treated mice was studied using
transmission electron microscopy. In saline-treated mice,
more endothelial cells developed a thin, irregular membrane
and contained inter-endothelial gaps and fenestrations
(Figure 2, left panel). In the vasostatin-treated mice, inter-
endothelial junctions appeared tight and fewer gaps were
observed (Figure 2, right panel).
Vasostatin reduced VEGF-A-induced vascular leakage
As VEGF-A is known to play a key role in enhancing vascular
leakage (Senger et al., 1983; Thurston et al., 1999) and
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Figure 1. Vasostatin inhibited vascular leakage in the inflamed skin.
(a) Mouse ear swelling test of vasostatin- and saline-treated mice after the
induction of CHS reactions. Ear swelling is expressed as the increase (change)
over the original ear thickness in mm. At least nine saline- and nine vasostatin-
treated mice were analyzed per time point (data are representative of three
independent experiments). (b) Twenty-four hours after the induction of an
CHS reaction, mice were injected intravenously with EBD and subsequently
perfused to clear the vessels of circulating dye. The EBD that leaked into
the surrounding tissue was extracted, and the level of protein-bound dye per
mg of tissue was quantified as a measure of vascular leakage. At least six
saline- and six vasostatin-treated mice were analyzed per time point (data are
representative of two independent experiments). (c) Thin sections (2 mm) of
inflamed skins of saline- and vasostatin-treated mice 24 and 48 hours after the
induction of CHS reactions. Data are expressed as mean7SEM. *Po0.05,
**Po0.01 and ***Po0.001. The two-sided unpaired Student’s t-test was used
for statistical analyses. Bar¼ 100mm.
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inflammation (Brown et al., 1995; Kunstfeld et al., 2004), we
investigated whether vasostatin controls plasma extravasation
directly by inhibiting VEGF-A-induced vascular permeability.
For this purpose, we quantified the extravasated EBD in
response to intradermally injected VEGF-A in the skin using a
modified Miles assay. Vasostatin diminished VEGF-A-in-
duced vascular hyperpermeability in the skin of mice by
37% (12.771.8 mg EBD, saline-treated; 8.070.4 mg EBD,
vasostatin-treated; Po0.05), whereas there was no difference
in the leakage induced by intradermal injections of saline
(3.270.5mg EBD, saline-treated; 1.970.5mg EBD, vasostatin-
treated) (Figure 3).
Vasostatin decreased the vascularity in the inflamed skin
of mice
Forty-eight hours following the onset of an inflammation, we
observed fewer blood vessels in the inflamed ears of
vasostatin-treated mice when compared to saline-treated mice
(Figure 4a). Computer-assisted morphometric image analyses
of the panendothelial cell marker CD31-immunostained blood
vessels revealed a significant decrease in the number of vessels
per mm ear length in the vasostatin-treated compared to
the saline-treated inflamed skins (50.871.4 blood vessels
(BV)/mm, saline-treated; 43.273.1 BV/mm, vasostatin-treated;
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Figure 2. Vasostatin suppressed the formation of inter-endothelial gaps
during an inflammation. Twenty-four hours after the induction of CHS
reactions, the skin of vasostatin- and saline-treated mice was harvested and
processed for electron microscopy. Representative images showing that in
(left panel) saline-treated mice endothelial cells display a thin, irregular
plasma membrane (fenestrations indicated by the arrows), and inter-
endothelial cell junctions (indicated by the asterisks) are discontinuous. In
contrast, in (right panel) vasostatin-treated mice, inter-endothelial junctions
(indicated by arrowhead) appear tight and fewer gaps and fenestrations are
observed. (upper panel) Bar¼ 1 mm and (lower panel) bar¼ 200 nm.
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Figure 3. Vasostatin inhibited VEGF-A induced vascular leakage in the skin.
For the modified Miles assay, EBD was intravenously injected in (a, upper
panel) saline-treated and (a, lower panel) vasostatin-treated mice. After
10 minutes, NaCl alone and human VEGF165 (200 ng) were separately
injected intradermally into the back skin. After 30 minutes, the skin area
containing the extravasated protein-bound dye was excised and the dye was
extracted from the tissue. Dye concentrations were measured at 620 nm using
a spectrophotometer. (b) The values obtained are expressed as total
nanograms of EBD extracted, and are a measure of the total amount of
protein-bound dye that extravasated in response to VEGF-A or NaCl
treatment. At least five saline- and five vasostatin-treated mice were used for
the experiments. Data are representative of two independent experiments.
Data are expressed as mean7SEM. *Po0.05. The two-sided unpaired
Student’s t-test was used for statistical analyses. Bar¼ 5 mm
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Figure 4. Decreased vascular remodeling in the inflamed skin following
vasostatin treatment. (a) Cryostat sections stained with the pan endothelial
cell marker CD31 to visualize vessels of (a, left panel) saline-treated and
(a, right panel) vasostatin-treated inflamed ear skins 48 hours following
antigen challenge. (b) Computer-assisted morphometric image analyses based
on these sections revealed a significant decrease in the number of blood
vessels per mm ear length following vasostatin treatment 48 hours after the
onset of the inflammation. (c) Vessel size distribution analyses were
performed to compare the frequency of vessels according to their size. At least
six saline- and six vasostatin-treated mice were used for these experiments.
Data are representative of two independent experiments. Data are expressed
as mean7SEM. *Po0.05. The two-sided unpaired Student’s t-test was used
for statistical analyses. Bar¼ 200mm.
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Po0.05) (Figure 4b). We then performed vessel size distribu-
tion analysis, where we compared the total number of vessels
grouped according to the size of the vessels. This analysis
revealed significantly fewer vessels (27%), with average vessel
size ranging in size between 500 and 2,000mm2 (9.870.9 BV/
mm, saline-treated; 7.170.2 BV/mm, vasostatin-treated;
Po0.05) (Figure 4c). The vessels that fall into this size range
are arterioles and post-capillary venules. As CD31 also
positively stains lymphatic endothelial cells, we could not
exclude a vasostatin-mediated effect on the lymphatic
vasculature. However, we observed no difference in the
average size, density, or size distribution of lymphatic vessels
as judged by LYVE-1-stained sections between the groups (data
not shown), confirming that vasostatin inhibited blood vascular
remodeling during CHS.
Vasostatin diminished the inflammatory infiltrate in the
inflamed skin
The infiltrating cells in the inflamed skin of vasostatin- and
saline-treated mice consisted mainly of neutrophil granulo-
cytes, macrophages, and lymphocytes. Analysis of the
inflammatory infiltrate using tissue sections immunostained
with antibodies directed against Ly6-G, to identify neutrophil
granulocytes revealed a significant decrease in the number of
neutrophils in vasostatin-treated mice compared to saline-
treated mice at 24 hours (437724 cells/mm, vasostatin-
treated and 592744 cells/mm, saline-treated; Po0.01) and
48 hours (330729 cells/mm, vasostatin-treated and
502735 cells/mm, saline-treated; Po0.01) following antigen
challenge (Figure 5a and b). Tissue sections immunostained
with antibodies directed against F4/80 used to identify
macrophages revealed a significant decrease in the number
of macrophages in vasostatin-treated mice compared to
saline-treated mice at 24 hours (101715 cells/mm, vasosta-
tin-treated and 214715 cells/mm, saline-treated; Po0.001)
and 48 hours (11375 cells/mm, vasostatin-treated and
245721 cells/mm, saline-treated; Po0.001) (Figure 5c and
d). Additionally, CD8 (CD8þ T cells) immunostains revealed
a significant decrease in the number of infiltrating CD8þ
T cells per mm ear length (2874 cells/mm, vasostatin-treated
and 4775 cells/mm, saline-treated; Po0.05) 48 hours fol-
lowing antigen challenge. No difference was observed in the
number of CD4þ T cells in the inflamed skin of both groups
or in the number of neutrophils, macrophages, CD8þ T cells,
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Figure 5. Vasostatin diminished inflammatory infiltrate in the inflamed skin. (a) Immunohistochemical stains of inflamed ear skin of vasostatin- and
saline-treated mice 24 hours after the induction of CHS reactions using an antibody directed against Ly6-G to visualize neutrophils. (b) Based on these stains,
computer-assisted image analyses were performed to determine the number of infiltrating neutrophils in the inflamed skin of vasostatin-treated mice compared
to saline-treated mice 24 and 48 hours following the onset of the inflammation. (c) Immunohistochemical stains of vasostatin- and saline-treated mice
24 hours into the inflammation using an antibody directed against F4/80 to visualize macrophages. (d) We performed computer-assisted image analyses based
on the F4/80-stained sections to quantify the number of macrophages in the vasostatin- and saline-treated mice 24 and 48 hours after the induction of CHS
reactions. At least six saline- and six vasostatin-treated mice were used for the experiments. Data are expressed as mean7SEM. **Po0.01 and ***Po0.001.
The two-sided unpaired Student’s t-test was used for statistical analyses. Bar¼ 100mm.
68 Journal of Investigative Dermatology (2007), Volume 127
R Huegel et al.
Vasostatin Suppressed Experimental Inflammations
and CD4þ T cells in the uninflamed skin of saline- and
vasostatin-treated mice.
Vasostatin diminished leukocyte–endothelium interaction in
inflamed skin
As the proangiogenic factor VEGF-A (Detmar et al., 1998)
and the antiangiogenic factor thrombospondin-2 (Lange-
Asschenfeldt et al., 2002) have been shown to influence the
leukocyte–endothelial interaction, we performed intravital
microscopy of blood vessels in uninflamed and inflamed skin
of mice treated with vasostatin or saline. The edema in the
inflamed ears of the mice in both groups made it difficult to
obtain reliable measurements at 24 hours post-challenge. We
therefore selected a time point of 6 hours following antigen
challenge, as our previous experiments indicated changes in
leukocyte adhesion as early as 2 hours following the onset of
inflammation, while maintaining optimal visualization of the
leukocytes in vivo. After injection of Rhodamine-6G,
intravital microscopy revealed no difference in the baseline-
rolling fraction in the uninflamed skin of the vasostatin- and
saline-treated mice. However, the rolling fraction of leuko-
cytes in the inflamed cutaneous blood vessels of vasostatin-
treated mice was decreased by 40% when compared to the
inflamed skin of saline-treated mice (4675%, vasostatin-
treated and 6973%, saline-treated; Po0.01) (Figure 6a). In
addition, whole mounts of inflamed ear skin after vascular
perfusion with the lectin Lycopersicon esculentum, which
binds to N-acetyl-D-glucosamine residues on the luminal
surface of vascular endothelial cells and to leukocytes
(Thurston et al., 1996), revealed decreased inflammatory
cells adherent to the endothelium of the blood vessels in the
vasostatin-treated compared to the saline-treated mice
24 hours following antigen challenge (Figure 6b), confirming
the data obtained from the intravital studies. We therefore
tested whether vasostatin directly influenced the expression
level of intercellular adhesion molecule, vascular cell
adhesion molecule, E-selectin, and VE-cadherin on the
surface of tumor necrosis factor-a-stimulated human dermal
microvascular endothelial cells in vitro using FACS analyses.
Although the stimulated human dermal microvascular
endothelial cells had increased levels of the tested cell
adhesion molecules, vasostatin at 10 or 100mg/ml had no
significant effect on the cell-surface expression of the tested
cell adhesion molecules.
Vasostatin blocked the upregulation of Ang-2 in the inflamed
ear skin
VEGF-A (Senger et al., 1983; Thurston et al., 1999) is a potent
inducer of vascular hyperpermeability, whereas Ang-1 has
been shown to inhibit vascular leakage (Thurston et al., 1999,
2000; Gamble et al., 2000). Therefore, we analyzed the
expression pattern of these factors as well as the Ang-1
antagonist Ang-2 using quantitative real-time reverse tran-
scription-PCR (RT-PCR). We found no difference in the
expression pattern of VEGF-A or Ang-1 mRNA between the
vasostatin- and saline-treated mice (Figure 7). However, we
found a more than 2-fold increase in the relative transcript
level of Ang-2 mRNA in the inflamed skin of saline-treated
mice when compared to the vasostatin-treated mice
(1.970.08, vasostatin-treated and 5.770.02, saline-treated;
Po0.001). There was no difference in the relative transcript
level of Ang-2 mRNA expression in the uninflamed skin of
either group (2.470.28, vasostatin-treated and 1.970.08,
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Figure 6. Diminished leukocyte–endothelial cell interaction following
vasostatin treatment. (a) Six hours after the induction of CHS reactions,
Rhodamine-6G was intravenously administered to visualize leukocytes in
vivo using intravital microscopy. The rolling fraction of leukocytes in post-
capillary venules in the skin of vasostatin- and saline-treated mice was
determined. At least four saline- and four vasostatin-treated mice were used
for the experiments. (b) Twenty-four hours after the onset of the inflammation,
vasostatin- and saline-treated mice were perfused with L. esculentum lectin
and whole mounts of the ears were used to visualize leukocytes adherent
to the wall of blood vessels (arrowheads). Four saline-treated and four
vasostatin-treated mice were used in the experiment. Data are expressed
as mean7SEM. **Po0.01. The two-sided unpaired Student’s t-test was
used for statistical analyses. Bar¼25 mm.
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Figure 7. Vasostatin inhibited inflammation-associated Ang-2 upregulation.
The mRNA expression of VEGF-A, Ang-1, and Ang-2 was measured in the
skin of saline-treated and vasostatin-treated mice 24 hours after the onset
of CHS reactions using real-time RT-PCR analyses. Four saline- and four
vasostatin-treated mice were used for the experiment. Data are expressed
as mean7SEM. ***Po0.001. The two-sided unpaired Student’s t-test
was used for statistical analyses.
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saline-treated) (Figure 6). Interestingly, elicitation of CHS
resulted in a 2-fold increase of Ang-2 mRNA expression in
saline- but not in vasostatin-treated mice.
DISCUSSION
Vasostatin treatment during experimental cutaneous CHS
responses resulted in a striking anti-inflammatory effect
evidenced by suppressed vasopermeability, edema forma-
tion, inflammatory cell influx, and angiogenesis. To our
knowledge, this is the first description of an angiogenesis
inhibitor with broad-range anti-inflammatory action. Previous
reports have demonstrated suppressed edema formation
during CHS reactions following the functional blockage of
the proangiogenic factor VEGF-A (Kunstfeld et al., 2004) and
reduced vascular leakage in CHS reactions in the presence of
the angiogenesis inhibitor TNP-470, caplostatin, and angio-
statin (Satchi-Fainaro et al., 2005).
Vascular integrity is fundamental in maintaining a physical
barrier between blood components and the underlying tissue.
During inflammation, plasma leakage is thought to occur
primarily through intercellular gaps that form between
endothelial cells or through the vesiculovacuolar organelle.
Plasma components are able to cross from the lumen into the
basement membrane through intercellular gaps or through
the direct transendothelial channel created by the vesiculo-
vacuolar organelles at sites of augmented vascular perme-
ability (Thurston et al., 1996; Dvorak and Feng, 2001).
Transmission electron microscopy studies of the inflamed
ears of vasostatin-treated mice revealed morphological
features associated with reduced vascular hyperpermeability.
Dermal capillaries and venules in the inflamed ear skin of
vasostatin-treated mice contained fewer gaps and the inter-
endothelial junctions in the vessels appeared tight compared
to the inflamed skin of saline-treated mice (Figure 2), as
revealed by transmission electron microscopy.
In our hands, vasostatin suppressed VEGF-A-induced
hyperpermeability in vivo as revealed by using a modified
Miles assay, but did not influence the expression of VEGF-A
in inflamed tissue as shown by real-time RT-PCR analyses.
However, vasostatin completely blocked the upregulation of
Ang-2 mRNA in vivo during the inflammation and this
observation could, at least in part, explain the increased
vascular integrity in the inflamed tissue following vasostatin
treatment. Ang-2 is a vascular destabilizer that, similar to
VEGF-A, has been shown to disrupt endothelial adherens
junctions, thereby contributing to inter-endothelial gap
formation (Carter, 2001) and is believed to be involved in
the formation of intercellular openings in tumor vessels,
leading to their leaky nature (Hashizume et al., 2000).
Moreover, Ang-2 is potently upregulated in the synovial
tissue in rheumatoid arthritis (Scott et al., 2002) and in
psoriatic lesions (Kuroda et al., 2001), highlighting an
important role of Ang-2 in inflammatory diseases. In contrast,
the vascular stabilizer Ang-1 has been demonstrated to play a
crucial role in controlling vascular leakage. For example,
mice with targeted epidermal overexpression of Ang-1 were
resistant to leakage induced by histamine, serotonin, and
mustard oil (Thurston et al., 1999), and adenoviral injection
of Ang-1 resulted in the inhibition of plasma leakage
normally induced by VEGF-A and mustard oil (Thurston
et al., 2000). Moreover, co-overexpression of Ang-1 with
VEGF-A reversed the enhanced baseline leakage seen in the
transgenic mice that overexpressed VEGF-A alone (Thurston
et al., 1999). Importantly, Ang-2 is a competitive antagonist
to Ang-1. Therefore, vasostatin could protect the interaction
between Ang-1 on vascular supporting cells and Tie-2 on endo-
thelial cells, promoting vascular quiescence and protecting
against plasma leakage.
In agreement with its known activity as an angiogenesis
antagonist, vasostatin treatment resulted in reduced inflam-
mation-associated vascular remodeling. Size distribution
analyses revealed a decrease in the frequency of vessels
ranging in size between 500 and 2,000mm2. In the skin, the
majority of vessels in this size range are post-capillary
venules (Braverman, 2000) and our data indicate that
vasostatin treatment resulted in fewer enlarged post-capillary
venules. This observation is in agreement with increasing
evidence, suggesting that inflammation-associated angiogen-
esis consists predominantly of the enlargement of existing
vessels as opposed to the growth of new capillaries (Braver-
man and Sibley, 1982; Lange-Asschenfeldt et al., 2002; Oura
et al., 2002; Kunstfeld et al., 2004).
Remodeled venules are not only sites of focal plasma
leakage but also of extensive inflammatory cell recruitment.
The infiltration of leukocytes into inflamed tissues requires a
chain of molecular events that mediate the rolling, adhesion,
and extravasation of these cells in post-capillary venules
(Springer, 1994; Butcher and Picker, 1996). Using intravital
microscopy, we found that the fraction of rolling leukocytes in
the inflamed skin of vasostatin-treated mice was significantly
decreased when compared to saline-treated mice, although no
difference was observed in the uninflamed skin of the two
groups. Concomitantly, we observed fewer neutrophils, macro-
phages, and CD8þ T cells infiltrating the inflamed skin
following vasostatin treatment. This contributed to the attenu-
ated inflammation as these inflammatory cells are important
sources of cytokines, chemokines, and growth factors that
promote and perpetuate the inflammatory response.
The connection between angiogenesis inhibitors and the
leukocyte–endothelial cell interaction is only beginning to be
appreciated. Transgenic VEGF-A overexpression led to en-
hanced rolling of leukocytes in cutaneous post-capillary
venules, and this effect was obliterated following systemic
treatment with antibodies directed against P- and E-selectin
(Detmar et al., 1998). Likewise, mice that lack the endogenous
angiogenesis inhibitor thrombospondin-2 are characterized by
enhanced leukocyte rolling and an increased number of
P-selectin-positive blood vessels (Lange-Asschenfeldt et al.,
2002). Recently, the endogenous angiogenesis inhibitor
angiostatin was found to inhibit the recruitment and adhesion
of neutrophils and macrophages to the endothelium and their
transmigration in vitro (Chavakis et al., 2005). In accordance,
vasostatin-treated mice showed reduced leukocyte–endothelial
cell interaction and diminished recruitment and transmigration
of inflammatory cells into inflamed tissue. However, we found
no significant change in the expression level of several cell
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adhesion molecules on the surface of tumor necrosis factor-a-
stimulated endothelial cells following vasostatin treatment. Yet,
the regulation of cell adhesion molecules by vasostatin cannot
be ruled out as leukocyte recruitment is not restricted to the
tested molecules. In fact, the Angs have been shown to induce
the expression of platelet-activating factor and the b2-integrin
complex on neutrophils, all of which are involved in the
adhesion of these cells to the endothelium (Lemieux et al.,
2005). As vasostatin inhibited inflammation-associated Ang-2
upregulation, this could provide a mechanism by which
vasostatin suppressed the rolling fraction of leukocytes and
the number of neutrophils infiltrating the inflamed skin.
Angiogenesis, whether vascular remodeling or neovascu-
larization, is an important component of inflammatory
diseases like rheumatoid arthritis and psoriasis. In rheumatoid
arthritis, the newly sprouted vasculature supports the devel-
opment of pathological tissue that invades the healthy tissue
and destroys the joints. Moreover, vascular hyperpermeability
resulting in gross tissue edema is a hallmark of many diseases
like contact dermatitis and uticaria. Current therapeutic
options are mainly restricted to immunosuppressive therapies
using corticosteroid treatment or application of other immuno-
suppressive agents (topical and systemic). These treatment
regimens are associated with substantial side effects including
super-infection and atrophy of the skin, and long-term use can
result in the development of malignant lesions.
Our results strongly suggest that the development of
treatment options using angiogenesis inhibitors might benefit
inflammatory diseases because of the observed suppression of
vascular leakage, leukocyte recruitment, and angiogenesis
following vasostatin treatment. Vasostatin is small, soluble,
and easy to produce. The recombinant protein seems to be
stable for more than 9 months in aqueous solutions, and the
effective dose of vasostatin (Pike et al., 1998) is much lower
than other angiogenesis inhibitors making vasostatin an
attractive therapeutic candidate. Additional studies are neces-
sary to evaluate the long-term effects of vasostatin treatment,
the possibility of topical application of vasostatin, and whether
it would benefit chronic inflammatory conditions.
MATERIALS AND METHODS
Animals
Eight- to 10-week-old female friends virus B mice (Charles River
Wiga GmbH, Sulzfeld, Germany) were used for experiments. Mice
were anesthetized with a mixture of ketamine (800 mg/10 g body
weight ketamine; Sigma-Aldrich, Taufkirchen, Germany) and avertin
(0.5 mg/10 g body weight 2,2,2,-tribromoethanol in 2.5% Rtamyl
alcohol; Sigma-Aldrich) as described (Lange-Asschenfeldt et al.,
2002), and the government of the state of Schleswig-Holstein,
Germany, approved all animal procedures.
Induction of CHS reactions in mice
CHS reactions were induced in the ear skin of 8- to 10-week-old
female friends virus B mice as described previously (Galli and
Hammel, 1984; Lange-Asschenfeldt et al., 2002). Mice were
sensitized by topical application of a 2% oxazolone (4-ethoxy-
methylene-2-phenyl-2-oxazoline-5-one; Sigma-Aldrich) solution in
acetone/olive oil (4:1 (vol/vol)) to the shaved abdomen (50 ml) and to
each paw (5ml). Five days after sensitization, the right ears were
challenged by topical application of 20 ml of a 1% oxazolone
solution, whereas the left ears were treated with the vehicle alone.
The thickness of vehicle- and oxazolone-treated ears (at least six
animals per time point) was measured using a dial thickness gage
(Mitutoyo, Japan) as described (Lange-Asschenfeldt et al., 2002). The
increase in ear thickness over the baseline levels, defined as the
thickness before the induction of the inflammation, was used as a
parameter for the extent of inflammation (Gad et al., 1986). Data are
expressed as mean7SE of the mean. The two-sided unpaired
Student’s t-test was used for statistical analyses.
Vasostatin treatment
Eight- to 10-week-old mice received intraperitoneal injection of
either 200 ml of 0.9% saline or were treated with the same volume
saline containing 130 mg of vasostatin (5.2 mg/kg body weight) 24
and 2 hours before challenge and every 24 hours during the post-
challenge period. Recombinant vasostatin was produced as de-
scribed (Pike et al., 1998). The purified protein was tested for
endotoxin by the Limulus Amebocyte Lysate kinetic-QCL assay and
was found to contain less than 5 endotoxin units/10 mg protein.
Evans blue permeability assay and modified Miles assay
Twenty-four hours after challenge, EBD (100 ml of a 1% solution in
0.9% NaCl; Sigma-Aldrich) was injected into the retro-orbital plexus
of anesthetized vasostatin- and saline-treated friends virus B mice.
Fifteen minutes after the injection, mice were perfused as described
(Thurston et al., 1999). Ears were removed, dried, weighed, and
incubated in 1 ml formamide (Sigma-Aldrich) at room temperature
for 5 days to extract the Evans blue from the tissue. Dye
concentration was measured at 620 nm using a spectrophotometer
and the value obtained was reported as ng/mg of ear tissue. For the
modified Miles assay, 24 hours after challenge, EBD was injected
into the retro-orbital plexus of anesthetized vasostatin- and saline-
treated friends virus B mice. After 10 minutes, 50 ml of 0.9%
NaCl alone and human VEGF165 (200 ng in 50 ml of saline;
Peprotech, London, UK) was injected intradermally into the back
skin as described previously (Miles and Miles, 1952; Claffey et al.,
1996; Oura et al., 2002). After 30 minutes, the area of skin that
included the blue spot resulting from leakage of the dye was
removed. EBD was extracted from the skin by incubation with
formamide for 5 days at room temperature, and the absorbance
of extracted dye was measured at 620 nm using a spectrophoto-
meter (Thurston et al., 1999). Data are expressed as mean7SEM.
The two-sided unpaired Student’s t-test was used for statistical
analyses.
L. esculentum lectin perfusions
Vascular perfusions were performed as described previously
(Thurston et al., 1996). Briefly, 24 hours after the onset of an
inflammation, 8-week-old vasostatin- or saline-treated mice were
anesthetized as described above, and 200 ml (1 mg/ml) of biotiny-
lated L. esculentum lectin (Vector Laboratories, Burlingame, CA) was
injected into the retro-orbital venous plexus. After this intravenous
injection, the animals were perfused via the left ventricle with
fixative (1% paraformaldehyde and 0.5% glutaraldehyde in phos-
phate-buffered saline (PBS), pH 7.4) followed by perfusion with PBS.
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Ears were removed, stained using the Vectastain Elite ABC kit (Vector
Laboratories), and examined by light microscopy.
Histology and immunohistochemistry
Mice were killed 24 and 48 hours after oxazolone challenge. Ears
were embedded in optimal cutting temperature compound (Sakura
Finetek Europe BV, Zoeterwoude, The Netherlands) and were frozen
on liquid nitrogen. Hematoxylin/eosin stains were performed
following standard protocols. Immunohistochemical stains were
performed on 10 mm cryostat sections as described (Streit et al.,
2000), using monoclonal rat antibodies against CD31 (clone MEC
13.3), Ly6-G (clone RB6-8C5), CD4 (clone H129.19), CD8 (clone
53–6.7), (all from BD Biosciences Pharmingen, Erembodem,
Belgium) or against F4/80 (clone CI: A3-1; Caltag Laboratories
GmbH, Hamburg, Germany), with the corresponding biotinylated
secondary antibody and the horseradish-peroxidase-conjugated
Vectastain Elite ABC kit (Vector Laboratories).
Transmission electron microscopy
Twenty-four and 48 hours after oxazolone challenge, ears of
vasostatin- and saline-treated mice were processed for electron
microscopy in a standard manner (Eady, 1985). Ears were subjected
to Karnovsky’s fixative that was then substituted by cacodylate
buffer. Specimens were post-fixed in 1.3% osmium tetroxide in
distilled water. Subsequent staining was performed with 2% uranyl
acetate in 50% ethanol. After dehydration in a graded alcohol series,
ethanol was substituted by propylene oxide and the ears were
embedded in Epon (Agar Scientific Ltd, Stansted, UK). Ultrathin
sections were double-stained with uranyl-acetate and lead citrate.
For microscopy and photographs, a Zeiss electron microscope (EM S
10; Leo, Oberkochen, Germany) was used.
Computer-assisted morphometric vessel analyses
CD31-labeled sections (at least six per time point) were examined
using an Axiotech 100 Upright Microscope (Zeiss, Gena, Germany),
and images were captured with a PowerShot G2 digital camera
(Canon Deutschland GmbH, Krefeld, Germany). Morphometric
analyses of digital images were performed using the IP-LAB software
(Scanalytics Inc., Fairfax, VA). At least three individual fields per
section were examined at original magnification  100, and the
number of vessels per mm ear length (Kunstfeld et al., 2004) and the
size of vessels were measured as described previously (Streit et al.,
1999). The determination of vessel density, that is, the number of
vessels per tissue area unit, has been frequently used to characterize
tumor and wound angiogenesis (Streit et al., 1999). However, the
marked increase of tissue area in inflamed mouse skin, resulting from
increased vascular leakage and edema formation, prevented a
meaningful analysis of vessel densities in our study. For this reason, a
modified method has been used to analyze vascularity in inflamed
murine skin, where the total number of vessels per mm of ear length
between the groups is compared (Kunstfeld et al., 2004). In order to
determine which type of vessels were mainly affected in response to
vasostatin treatment, we performed size distribution analyses. In
these analyses, we grouped the total number of vessels according to
their size. Capillaries are represented by the vessel population with a
size under 100mm2. Smaller post-capillary venules and arterioles are
found in the group of vessels with a size ranging between 100 and
500mm2. Larger post-capillary venules and arterioles are represented
by the group of vessels with a size of 500–2,000 mm2. Data are
expressed as mean7SEM. The two-sided unpaired Student’s t-test
was used to analyze differences in the number of vessels per mm ear
length and the average vessel size.
Computer-assisted morphometric inflammatory cell analysis
CD4-, CD8-, Ly6-G-, and F4/80-labeled sections (at least six per time
point) were examined using an Axiotech 100 Upright Microscope
(Zeiss), and images were captured with a PowerShot G2 digital
camera (Canon Deutschland GmbH). Morphometric analyses of
digital images were performed using the IP-LAB software (Scanaly-
tics). At least three individual fields per section were examined at
original magnification  100, and the number of immunoreactive
cells per mm ear length was determined as a measure of cellular
infiltration. Data are expressed as mean7SEM. The two-sided
unpaired Student’s t-test was used to analyze differences in the
inflammatory cell number.
Intravital microscopy of cutaneous blood vessels
The animal preparation and the technical and experimental aspects
of the customized intravital microscopy apparatus have been
described previously (von Andrian and M’Rini, 1998). Briefly,
6 hours after challenge, 8-week-old friends virus B mice were
treated with vasostatin or saline and anesthetized with a mixture of
ketamine and avertin as described above. The fluorescent dye
Rhodamine-6G (20 mg/kg in PBS; Sigma-Aldrich) was administered
intravenously to visualize circulating leukocytes by using a VE-100
SIT Video Enhancement System (DAGE-MTI of MC Inc., Michigan
City, IN). At least three superficially located post-capillary and small
collecting venules in the ear skin were randomly chosen and
recorded during 1–3 minutes intervals to assess the baseline rolling
interactions of leukocytes. The rolling fraction was calculated as the
number of rolling leukocytes multiplied by 100 divided by the total
leukocyte flux as described (von Andrian and M’Rini, 1998). Data
are expressed as mean7SEM. The two-sided unpaired Student’s
t-test was used to analyze differences in the rolling fraction.
FACS analysis
Human dermal microvascular endothelial cells were isolated from
neonatal foreskins and cultivated as described (Richard et al., 1998).
Human dermal microvascular endothelial cells were seeded onto
10 cm dishes and starved overnight in endothelial basal media
(Cambrex Bioscience, Walkersville, MD) containing 2% fetal bovine
serum. Cells were washed several times with PBS and pre-treated
with endothelial basal media with 0.1% BSA with or without
vasostatin (at 10 or 100 mg/ml) for 1 hour at 371C before stimulation
with tumor necrosis factor-a (20 ng/ml, R&D Systems, Minneapolis,
MN). After 6 hours of incubation, the cells were washed with ice-
cold PBS and detached with 1 mM EDTA in PBS. Cell-surface staining
was performed with anti-human vascular cell adhesion molecule
mAb (BD Pharmingen, Rockville, MD), anti-human mAb CD54/
intercellular adhesion molecule, anti-human mAb CD62e/E-selectin
(both Lab Vision, Freemont, CA), anti-human mAb CD144/VE-
cadherin (R&D Systems, Minneapolis, MN) and corresponding
isotypes (1:10 dilution) at 41C for 30 minutes in 1% fetal bovine
serum in PBS. After washing, the cells were incubated with an Alexa
fluor-conjugated anti-mouse mAb (1:200 dilution) for 30 minutes
(Molecular Probes, Carlsbad, CA). Following a final washing step,
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the cells were subjected to flow cytometry analysis. Data were
collected using a FACScalibur cytofluorometer (Becton Dickinson, San
Jose, CA) and analyzed using CELLQuest software (Becton Dickinson).
Quantification of mRNA expression using real-time RT-PCR
Real-time RT-PCR analyses were performed in a fluorescence
temperature cycler (LightCycler, Roche Applied Science, Mannheim,
Germany) as described previously (Harder and Schroder, 2002).
Briefly, total RNA from inflamed and uninflamed mouse skin from
both vasostatin- and saline-treated mice 24 hours after antigen
challenge was extracted using Tri-reagent (Sigma-Aldrich), treated
with RNase-Free DNase (Qiagen, Germany), and 2 mg of total RNA
was reverse-transcribed using the First Strand cDNA Synthesis Kit for
RT-PCR (Roche Applied Science). The cDNA corresponding to 50 ng
of RNA served as a template in a 20 ml reaction containing 4 mM
MgCl2, 0.5 mM each primer, and 2ml LightCycler-FastStart DNA
Master SYBR Green I mixture (Roche Applied Science).
Samples were incubated for an initial denaturing at 951C for
10 minutes, followed by 45 cycles, each cycle consisting of 951C for
15 seconds, 601C (touchdown of 11C/cycle from 66 to 601C) for
5 seconds, and 721C for 10 seconds. Cycle-to-cycle fluorescence
emission readings were monitored at 721C at the end of each cycle
and analyzed using LightCycler Software (Roche Applied Science).
Melting curves were generated after each run to confirm amplifica-
tion of specific transcripts. All quantifications were normalized to the
housekeeping gene porphobilinogen deaminase. Standard
curves were obtained for each primer set with serial dilutions of
cDNA. Data are expressed as mean7SEM. The two-sided
unpaired Student’s t-test was used to analyze differences in the
mRNA levels.
Primer sequences:
Mouse porphobilinogen deaminase (Wang et al., 2004): FP,
50-CGG CCA CAA CCG CGG AAG AA-30 and RP, 50-GTC TCC CGT
GGT GGA CAT AGC AAT GA-30.
Mouse Ang-1 (Elson et al., 2001): FP, 50-GCA AAT GCG CTC
TCA TGC TA-30 and RP, 50- GGA GTA ACT GGG CCC TTT GAA-30.
Mouse Ang-2 (Elson et al., 2001): FP, 50-TGA CAG CCA CGG
TCA ACA AC-30 and RP, 50-ACG GAT AGC AAC CGA GCT CTT-30.
Mouse VEGF-A (Kunstfeld et al., 2004): FP, 50-CAT CTT CAA
GCC GTC CTG TGT-30 and RP, 50-CAG GGC TTC ATC GTT ACA
GCA-30; annealing temperature 601C for all primers.
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